Stock CMPX COMPASS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Compass Therapeutics, Inc. OTC Markets

Equities

CMPX

US20454B1044

Real-time Estimate Cboe BZX
Other stock markets
 01:15:29 2024-07-12 pm EDT 		5-day change 1st Jan Change
1.095 USD -69.15% Intraday chart for Compass Therapeutics, Inc. +32.67% 0.00%
Jul. 01 Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2000 Growth Index CI
Jul. 01 Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell Microcap Growth Index CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
AQ
Compass Therapeutics : 2024 Proxy Supplemental
PU
Compass Therapeutics Announces CEO Transition
AQ
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
AQ
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
AQ
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
AQ
Compass Therapeutics : 2024 Proxy
PU
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data
PU
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
AQ
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
AQ
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
AQ
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
AQ
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
AQ
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
AQ
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
AQ
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
AQ
Compass Therapeutics Provides Corporate Update
AQ
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Compass Therapeutics to Participate in Upcoming Investor Events
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPX Stock
  4. CMPX Stock
  5. News Compass Therapeutics, Inc.
  6. Press Releases